Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL554224 | 0.84 | SMPD3 (0.39) | SMPD3 | |
| SCHEMBL553239 | 0.84 | KDM4E (0.32) | KDM4EHSD17B10LMNAALDH1A1HPGD | |
| SCHEMBL553498 | 0.84 | KDM4E (0.32) | KDM4EHSD17B10LMNAALDH1A1HPGD | |
| SCHEMBL554214 | 0.81 | KDM4E (0.30) | KDM4EHSD17B10LMNA | |
| SCHEMBL552667 | 0.81 | KDM4E (0.30) | KDM4EHSD17B10LMNA | |
| SCHEMBL554190 | 0.78 | — | — | |
| SCHEMBL14355982 | 0.75 | KDM4E (0.34) | KDM4EHSD17B10LMNAALDH1A1HPGD | |
| SCHEMBL798499 | 0.75 | KDM4E (0.34) | KDM4EHSD17B10LMNAALDH1A1HPGD | |
| SCHEMBL11979453 | 0.75 | SMPD3 (0.39) | SMPD3 | |
| SCHEMBL553205 | 0.75 | SMPD3 (0.33) | SMPD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210214323-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2021-07-15 | — | — | US | disclosed |
| US-10995078-B2 | Compounds and compositions for inhibition of FASN | FORMA THERAPEUTICS, INC. (US) | 2021-05-04 | — | — | US | disclosed |
| US-20200347025-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2020-11-05 | — | — | US | disclosed |
| US-10472342-B2 | Compounds and compositions for inhibition of FASN | FORMA THERAPEUTICS, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| US-20190241532-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2019-08-08 | — | — | US | disclosed |
| CN-109153646-A | Pyridine dicarboxamide derivatives as bromine structural domain inhibitor | 葛兰素史克知识产权第二有限公司 | 2019-01-04 | — | — | CN | disclosed |
| US-20180050997-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2018-02-22 | — | — | US | disclosed |
| US-20170368032-A1 | Imidazole-Based Antimicrobial Agents | PROCOMCURE BIOTECH GMBH (AT) | 2017-12-28 | — | — | US | disclosed |
| US-20170340613-A1 | Novel Imidazole-Based Heterocyclic Compounds | PROCOMCURE BIOTECH GMBH (AT) | 2017-11-30 | — | — | US | disclosed |
| US-20170334887-A1 | Imidazole-Based Antimicrobial Agents | PROCOMCURE BIOTECH GMBH (AT) | 2017-11-23 | — | — | US | disclosed |
| US-20130078391-A1 | Complexes Of Imidazole Ligands | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2013-03-28 | — | — | US | disclosed |
| US-8236832-B2 | Thiazoles, imidazoles, and pyrazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-20120121806-A1 | Complexes Of Imidazole Ligands | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120035351-A1 | Volatile Imidazoles and Group 2 Imidazole Based Metal Precursors | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2012-02-09 | — | — | US | disclosed |
| EP-2371821-A1 | Volatile imidazoles and group 2 imidazole based metal precursors | Air Products and Chemicals, Inc. (US) | 2011-10-05 | — | — | EP | disclosed |
| US-20090306155-A1 | THIAZOLES, IMIDAZOLES, AND PYRAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-12-10 | — | — | US | disclosed |
| US-7589214-B2 | 2-Cyclopentyl-4-(4-phenoxyphenyl)thiazole-5-carboxamide; amidation; oxidation; cyclization; | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-09-15 | — | — | US | disclosed |
| US-7507757-B2 | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-03-24 | — | — | US | disclosed |
| US-7452907-B2 | Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-18 | — | — | US | disclosed |
| US-20070298065-A1 | 2-Cyclopentyl-4-(4-phenoxyphenyl)thiazole-5-carboxamide; amidation; oxidation; cyclization; | VERTEX PHARMACEUTICALS INCORPORATED | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130078391-A1 | Complexes Of Imidazole Ligands | ICOSLG, CLTC, PICALM | SMPD3 4296/4885KDM4E 2146/4885HSD17B10 4568/4885 |
| US-20180050997-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FASN, FABP1, SCD | SMPD3 316/4885KDM4E 4419/4885HSD17B10 140/4885 |
| US-20170334887-A1 | Imidazole-Based Antimicrobial Agents | TLR5, NISCH, SLC11A2 | SMPD3 632/4885KDM4E 2893/4885HSD17B10 3638/4885 |
| US-20200347025-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FASN, FABP1, SCD | SMPD3 372/4885KDM4E 4280/4885HSD17B10 138/4885 |
| US-20090306155-A1 | THIAZOLES, IMIDAZOLES, AND PYRAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | MAP3K5, MAP3K1, MAP3K20 | SMPD3 3187/4885KDM4E 2143/4885HSD17B10 4045/4885 |
| US-10472342-B2 | Compounds and compositions for inhibition of FASN | FASN, FABP1, SCD | SMPD3 372/4885KDM4E 4280/4885HSD17B10 138/4885 |
| US-20120035351-A1 | Volatile Imidazoles and Group 2 Imidazole Based Metal Precursors | CACNG5, BST2, API5 | SMPD3 2782/4885KDM4E 1388/4885HSD17B10 4813/4885 |
| US-20120121806-A1 | Complexes Of Imidazole Ligands | ICOSLG, CLTC, PICALM | SMPD3 4296/4885KDM4E 2146/4885HSD17B10 4568/4885 |
| US-20170368032-A1 | Imidazole-Based Antimicrobial Agents | TLR5, NISCH, SLC11A2 | SMPD3 632/4885KDM4E 2893/4885HSD17B10 3638/4885 |
| US-20190241532-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FASN, FABP1, SCD | SMPD3 316/4885KDM4E 4419/4885HSD17B10 140/4885 |
| US-20170340613-A1 | Novel Imidazole-Based Heterocyclic Compounds | SLC11A2, MIF, NISCH | SMPD3 940/4885KDM4E 2876/4885HSD17B10 1785/4885 |
| US-20210214323-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FASN, FABP1, SCD | SMPD3 316/4885KDM4E 4419/4885HSD17B10 140/4885 |
| US-10995078-B2 | Compounds and compositions for inhibition of FASN | FASN, FABP1, SCD | SMPD3 372/4885KDM4E 4280/4885HSD17B10 138/4885 |
| US-20070298065-A1 | 2-Cyclopentyl-4-(4-phenoxyphenyl)thiazole-5-carboxamide; amidation; oxidation; cyclization; | PDXK, PRKACA, PRKACB | SMPD3 1383/4885KDM4E 1137/4885HSD17B10 2790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.